TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28704520

Group type: EXPERIMENTAL
Intervention: Self-affirmation exercise with correcting information about MMR vaccine and autism
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Self-affirmation exercise without correcting information
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control passage about bird feeding with correcting information about MMR vaccine and autism
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control condition reflecting on least-personally-important values
Number of subjects: 585
Study: 26216229

Group type: EXPERIMENTAL
Intervention: Novel method for wear analysis in tantalum cups
Number of subjects: 46

Group type: COMPARATOR
Intervention: Gold standard RSA
Number of subjects: 46
Study: 23247973

Group type: EXPERIMENTAL
Intervention: Thyreogutt® mono (Lycopus europaeus) in prolective assessment for 4 weeks
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Thyreogutt® mono (Lycopus europaeus) in retrolective assessment for at least one course (4 weeks) during the previous 2 years
Number of subjects: 403

Group type: COMPARATOR
Intervention: Control cohort receiving no drug treatment
Number of subjects: 403
Study: 21307136

Group type: COMPARATOR
Intervention: Active controls (VO2max > 40 ml/kg · min)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy sedentary controls (FH-)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy sedentary controls (FH+)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Obese participants
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: T2DM
Number of subjects: 58
Study: 19041438

Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 41

Group type: COMPARATOR
Intervention: DMPA
Number of subjects: 41
Study: 17109685

Group type: EXPERIMENTAL
Intervention: Talpha1 therapy (1.6 mg, two times a week for 26 weeks)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Talpha1 therapy (1.6 mg, two times a week for 52 weeks)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no specific treatment for 18 months)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Talpha1 therapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 15569282

Group type: EXPERIMENTAL
Intervention: Standard care plus education by telephone (155 children)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard care (155 children)
Number of subjects: 310
Study: 11789123

Group type: EXPERIMENTAL
Intervention: 600 mg of St. John's wort extract WS 5572 daily
Number of subjects: 2166

Group type: EXPERIMENTAL
Intervention: 1200 mg of St. John's wort extract WS 5572 daily
Number of subjects: 2166
Study: 9247843

Group type: EXPERIMENTAL
Intervention: Homoeopathic treatment (Aconitum napellus, Apis mellifica, Belladonna, Capsicum, Chamomilla, Kalium bichromicum, Lachesis, Lycopodium, Mercurius solubilis, Okoubaka, Pulsatilla, Silicea)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conventional therapy (nasal drops, antibiotics, secretolytics and/or antipyretics)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Homoeopathic treatment
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 131
Study: 7967986

Group type: EXPERIMENTAL
Intervention: Weight support and standing on a moving treadmill
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training programme
Number of subjects: 0
Study: 3583229

Group type: EXPERIMENTAL
Intervention: Aspirin (330 mg) and dipyridamole (75 mg) taken three times daily for three weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30957446

Group type: EXPERIMENTAL
Intervention: Moxibustion at Shenque (CV 8) and warm needling at Guanyuan (CV 4) and Sanyinjiao (SP 6)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Warm needling at Guanyuan (CV 4) and Sanyinjiao (SP 6)
Number of subjects: 120
Study: 28520519

Group type: EXPERIMENTAL
Intervention: Oil-based contrast
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Water-based contrast
Number of subjects: 1119
Study: 25886810

Group type: EXPERIMENTAL
Intervention: External stenting
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonstented SVG
Number of subjects: 30
Study: 23177399

Group type: EXPERIMENTAL
Intervention: Patient-centered interview (PCI)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Clinician-centered interview (CCI)
Number of subjects: 9
Study: 21982657

Group type: EXPERIMENTAL
Intervention: Myoblasts (400 million)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Myoblasts (800 million)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 18163420

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 10057

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10057
Study: 17177154

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta‐1a 15 micrograms once a week
Number of subjects: 16

Group type: COMPARATOR
Intervention: No disease-modifying therapy
Number of subjects: 16
Study: 12915289

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 980

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 980
Study: 10972697

Group type: EXPERIMENTAL
Intervention: Epoetin alpha to achieve hemoglobin levels of 10 g/dL
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Epoetin alpha to achieve hemoglobin levels of 13.5 g/dL
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Normalization of hemoglobin
Number of subjects: 146
Study: 8776187

Group type: EXPERIMENTAL
Intervention: Indomethacin and thymopentin for immunomodulation (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group A (no intervention)
Number of subjects: 20
Study: 1474076

Group type: EXPERIMENTAL
Intervention: Low protein (LP) = 0.86 g protein.kg‐1.day‐1 for 13 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate protein (MP) = 1.40 g protein.kg‐1.day‐1 for 13 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High protein (HP) = 2.40 g protein.kg‐1.day‐1 for 13 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low protein (LP) for sedentary subjects (S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High protein (HP) for sedentary subjects (S)
Number of subjects: 0
Study: 6379859

Group type: EXPERIMENTAL
Intervention: Tigason (vitamin A-acid analog) for 8 months
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Tigason
Number of subjects: 73
Study: 30062823

Group type: EXPERIMENTAL
Intervention: T1DM
Number of subjects: 47
Study: 27491533

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitisation and Reprocessing (EMDR) therapy
Number of subjects: 108
Study: 26591355

Group type: EXPERIMENTAL
Intervention: Yishen Qingre Huashi Recipe (YQHR)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Losartan Potassium Tablet (50 mg once per day)
Number of subjects: 121
Study: 23659074

Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 0
Study: 20506254

Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Ofatumumab 700 mg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Ofatumumab 1000 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Ofatumumab (all doses combined)
Number of subjects: 264
Study: 18160461

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (25, 50, 125, 300, or 600 mg im) for 20 weeks
Number of subjects: 121
Study: 17063637

Group type: EXPERIMENTAL
Intervention: Gliclazide modified release (MR) tablets (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial gliclazide standard preparation (30 mg)
Number of subjects: 0
Study: 14628980

Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 10699688

Group type: EXPERIMENTAL
Intervention: docetaxel plus best supportive care (BSC)
Number of subjects: 207

Group type: COMPARATOR
Intervention: best supportive care (BSC)
Number of subjects: 207
Study: 9243044

Group type: EXPERIMENTAL
Intervention: Isoniazid (300 mg/d)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg/d)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pyrazinamide (1,500 mg/d)
Number of subjects: 29
Study: 8478235

Group type: EXPERIMENTAL
Intervention: Hyperthermia treatment (60 min, 1 or 2 times per week during irradiation)
Number of subjects: 111
Study: 2945109

Group type: EXPERIMENTAL
Intervention: 2 days of bed rest (Group I)
Number of subjects: 203

Group type: COMPARATOR
Intervention: 7 days of bed rest (Group II)
Number of subjects: 203
Study: 31564236

Group type: EXPERIMENTAL
Intervention: Outpatient physical therapy intervention including a 1-hour initial assessment and individualized treatment plans
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Posttreatment 10-meter gait speed measurement
Number of subjects: 50
Study: 29111115

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg/day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 24504832

Group type: EXPERIMENTAL
Intervention: Clubhouse
Number of subjects: 167

Group type: COMPARATOR
Intervention: PACT
Number of subjects: 167
Study: 24662192

Group type: EXPERIMENTAL
Intervention: Exenatide 10ug bd for 12 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no exenatide)
Number of subjects: 44
Study: 22441448

Group type: EXPERIMENTAL
Intervention: Single injection of 1 ml betamethasone and 1 ml prilocaine on the lateral epicondyle at the point of maximum tenderness.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Injection of the same drug mixture with needle tip redirected and reinserted down the bone approximately 30 to 40 times without emerging from the skin, creating a hematoma.
Number of subjects: 80
Study: 19933822

Group type: EXPERIMENTAL
Intervention: Cushing's syndrome treatment (normalization of corticosteroid excess)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no treatment for Cushing's syndrome)
Number of subjects: 15
Study: 16904718

Group type: EXPERIMENTAL
Intervention: CQ 50 mg/kg
Number of subjects: 729

Group type: COMPARATOR
Intervention: CQ 25 mg/kg
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: AQ 15 mg/kg
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: AQ 30 mg/kg
Number of subjects: 729
Study: 16168215

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GnRH agonist (group A)
Number of subjects: 60
Study: 11787985

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg zinc as gluconate, orally, for 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 9254876

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 21
Study: 8495450

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hyperventilation attack
Number of subjects: 18
Study: 3505872

Group type: EXPERIMENTAL
Intervention: Mnemonic training (8 hours)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 76
Study: 31987566

Group type: EXPERIMENTAL
Intervention: Geotherapy combined with kinesiotherapy (GK)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Kinesiotherapy (K)
Number of subjects: 48
Study: 28945160

Group type: EXPERIMENTAL
Intervention: Telemedicine-delivered behaviour activation treatment (BAT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Same-room behaviour activation treatment (BAT)
Number of subjects: 90
Study: 27059816

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg/week
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg/week
Number of subjects: 409

Group type: COMPARATOR
Intervention: Metformin ≥1500 mg/day
Number of subjects: 409
Study: 24063860

Group type: EXPERIMENTAL
Intervention: sorafenib plus interleukin-2 (IL-2) 400 mg twice daily plus subcutaneous IL-2 4.5 million international units (MIU) five times per week for 6 weeks every 8 weeks (arm A)
Number of subjects: 128

Group type: COMPARATOR
Intervention: sorafenib alone (arm B)
Number of subjects: 128
Study: 21463474

Group type: EXPERIMENTAL
Intervention: Remoxy 40 mg whole (fed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remoxy 40 mg chewed (fed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxycodone ER 40 mg (crushed, fasted)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxycodone IR 40 mg (crushed, fasted)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxycodone ER 40 mg (whole and chewed)
Number of subjects: 0
Study: 18375416

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 16332

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16332
Study: 16434523

Group type: EXPERIMENTAL
Intervention: Computer-assisted navigated total knee arthroplasty
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard conventional surgical technique using intramedullary alignment guides
Number of subjects: 24
Study: 12927657

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg daily)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Amiloride (10 mg daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 10694099

Group type: EXPERIMENTAL
Intervention: ICT Tuberculosis test for SM+ patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICT Tuberculosis test for EPT patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prevalence of SM+ patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prevalence of confirmed EPT patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICT Tuberculosis assay
Number of subjects: 0
Study: 9301442

Group type: EXPERIMENTAL
Intervention: B-CHOP-M (bleomycin, cyclophosphamide, doxorubicin, vincristine, prednisolone and methotrexate)
Number of subjects: 325

Group type: COMPARATOR
Intervention: PEEC-M (methylprednisolone, vindesine, etoposide, chlorambucil and methotrexate) alternating with B-CHOP-M
Number of subjects: 325
Study: 8359098

Group type: EXPERIMENTAL
Intervention: metformin
Number of subjects: 12

Group type: COMPARATOR
Intervention: glibenclamide
Number of subjects: 12
Study: 3675008

Group type: EXPERIMENTAL
Intervention: Oral phenytoin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular gold
Number of subjects: 60
Study: 29290068

Group type: EXPERIMENTAL
Intervention: 0.5% minoxidil cream applied twice daily for 2 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: 2% diltiazem cream applied twice daily for 2 weeks
Number of subjects: 88
Study: 26996811

Group type: EXPERIMENTAL
Intervention: Rotator cuff and scapular strengthening exercises for 4 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 36
Study: 24239790

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) therapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combination therapy (cathodal tDCS + VR)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study: 23725851

Group type: EXPERIMENTAL
Intervention: Irinotecan plus panitumumab (IrPan)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Irinotecan
Number of subjects: 460
Study: 19946216

Group type: EXPERIMENTAL
Intervention: Telephone recall system managed by pediatricians
Number of subjects: 205

Group type: COMPARATOR
Intervention: Anonymous recall system
Number of subjects: 205
Study: 19040589

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1235

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1235
Study: 21974764

Group type: EXPERIMENTAL
Intervention: Valsartan 10-20 mg
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Valsartan 40-80 mg
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Valsartan 80-160 mg
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Valsartan (after re-randomization)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo (after re-randomization)
Number of subjects: 261
Study: 15668554

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional chest physical treatments
Number of subjects: 11
Study: 11867177

Group type: EXPERIMENTAL
Intervention: Corticosteroids (28-day course)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Polymorphonuclear neutrophils (PMN)
Number of subjects: 25

Group type: COMPARATOR
Intervention: AH patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: LPS-stimulated blood PMN from AH patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Formyl-Methionyl-Leucyl-Phenylalanine-induced PMN
Number of subjects: 25
Study: 9517989

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 1000 mg three times/day
Number of subjects: 994

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 1000 mg three times/day (at protocol amendment)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Placebo (at protocol amendment)
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) for patients taking didanosine (ddI)
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) for patients not taking didanosine (ddI)
Number of subjects: 994
Study: 8044950

Group type: EXPERIMENTAL
Intervention: Aortic counterpulsation
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 182
Study: 3261547

Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection in the antecubital fossa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous propofol mixed with lignocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slowing the speed of injection
Number of subjects: 0
Study: 31035808

Group type: EXPERIMENTAL
Intervention: Perceived cancer-related benefits of quitting smoking
Number of subjects: 303
Study: 29323616

Group type: EXPERIMENTAL
Intervention: Advanced bipolar instruments (LigaSure)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional bipolar instruments (Robi forceps)
Number of subjects: 68
Study: 26445384

Group type: EXPERIMENTAL
Intervention: Warm vertical compaction (WVC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Single match tapered size cone technique (SMTSC)
Number of subjects: 16
Study: 25719444

Group type: EXPERIMENTAL
Intervention: Sevoflurane-ketamine (group SK)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sevoflurane-saline (group SS)
Number of subjects: 100
Study: 24389403

Group type: EXPERIMENTAL
Intervention: 60 mL of red wine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mL of vodka
Number of subjects: 0

Group type: COMPARATOR
Intervention: Congeners of red wine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 0
Study: 20574104

Group type: EXPERIMENTAL
Intervention: Triple-lumen peripherally inserted central catheter (PICC)
Number of subjects: 50
Study: 18675399

Group type: EXPERIMENTAL
Intervention: High stress (prior to receiving methadone dose)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Low stress (immediately following methadone dose)
Number of subjects: 41
Study: 17186094

Group type: EXPERIMENTAL
Intervention: Low dose streptokinase (500,000 to 750,000 U)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Classical therapy (1.5 million U)
Number of subjects: 166
Study: 14595471

Group type: EXPERIMENTAL
Intervention: Breath-holding challenge test
Number of subjects: 77
Study: 10788199

Group type: EXPERIMENTAL
Intervention: Research-based teacher-delivered sex education programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trigger video sessions and role-play techniques for sexual negotiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Same-sex student groups for reflection on gendered construction of sexuality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Materials tailored to recipients' circumstances
Number of subjects: 0
Study: 8891642

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonpsychiatric subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 1680135

Group type: EXPERIMENTAL
Intervention: Low dosage of zidovudine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High dosage of zidovudine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 25
Study: 6134543

Group type: EXPERIMENTAL
Intervention: lorazepam 3 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: diazepam 15 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: diazepam 5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: lorazepam 1 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 30531464

Group type: EXPERIMENTAL
Intervention: Microdoses of recombinant human erythropoietin (rHuEpo) (20‐40 IUkg) administered twice per week for 7 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo administered twice per week for 7 weeks
Number of subjects: 14
Study: 27534639

Group type: EXPERIMENTAL
Intervention: Iodine supplementation during pregnancy
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300
Study: 24449229

Group type: EXPERIMENTAL
Intervention: Telehealth personalized risk assessment and communication intervention
Number of subjects: 481

Group type: COMPARATOR
Intervention: Mailed educational brochure
Number of subjects: 481
Study: 22420466

Group type: EXPERIMENTAL
Intervention: Sevoflurane sedation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 100
Study: 20831358

Group type: EXPERIMENTAL
Intervention: 5000 ppm fluoride toothpaste with no post-brushing water rinsing
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1450 ppm fluoride toothpaste with three sessions of post-brushing water rinsing
Number of subjects: 20
Study: 18053628

Group type: EXPERIMENTAL
Intervention: Modafinil treatment for 21 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment for 21 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Modafinil treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20